Senores Pharmaceuticals Limited — Investor Meet, 19-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Senores Pharmaceuticals reported strong FY26 performance, with revenue up 62% to INR 664 crores and PAT up 108% to INR 122 crores, surpassing guidance. Q4 saw 66% revenue growth and 78% PAT growth, with EBITDA margin at 32.7%.

Management projects FY27 revenue growth of 30-40% and PAT growth of 50-60%, expecting blended EBITDA margins of 29-31%. This confidence stems from a robust product pipeline, expanded capacities, and strategic acquisitions. The company acquired Apnar Pharma (USFDA-approved) and Zoraya Pharmaceuticals to bolster US presence and launched Amerisyn JV for government contracts. 30 more approved ANDAs are slated for launch in the next 6-8 quarters. Regulated markets grew 75% in FY26, emerging markets 20%, and Indian branded generics nearly 5x.

Key highlights from Q&A include Apnar’s impact on working capital, expected FY27 revenue of INR 80-100 crores from Apnar, and INR 70-80 crores from Amerisyn with over 40% EBITDA margins. Emerging market EBITDA margins are anticipated to sustain at 18-21%. FY27 capex of INR 200 crores (half from IPO funds) should lead to free cash flow generation. Management projects confidence in its long-term strategy, aiming for INR 2,500-3,000 crores US revenue in 3-4 years, despite conservative FY27 guidance due to global uncertainties.